the disease
What is Cardiac Amylodoisis
Cardiac amyloidosis is a disease characterized by the deposition of misfolded amyloid proteins in the heart, leading to structural and functional impairments. It is most commonly caused by either transthyretin (ATTR) or light-chain (AL) amyloidosis, each with distinct pathophysiological mechanisms. ATTR amyloidosis can be hereditary or acquired, while AL amyloidosis results from plasma cell dyscrasias. The disease often manifests as restrictive cardiomyopathy, causing progressive heart failure with symptoms such as dyspnea, fatigue, and peripheral edema. Diagnosis involves imaging techniques like echocardiography and cardiac MRI, biomarkers such as NT-proBNP, and, in some cases, tissue biopsy with Congo red staining.
Treatment varies depending on the type, with ATTR amyloidosis managed through transthyretin stabilizers or gene-silencing therapies, and AL amyloidosis requiring chemotherapy or autologous stem cell transplantation.
Early diagnosis is crucial, as the prognosis depends on the extent of cardiac involvement and the availability of effective treatments.
Area Under Curve of the model
Precision of the model
Amylospot: AI-Powered Precision for Cardiac Amyloidosis early detection
Amylospot is Bioquantis' cutting-edge AI-based software, designed to assist cardiologists—both experts and non-experts in transthyretin cardiac amyloidosis (aTTR). By leveraging advanced artificial intelligence, Amylospot empowers specialists familiar with the disease to refine their assessments while providing essential support to general cardiologists in identifying early signs of amyloid deposition. This facilitates timely referrals for further diagnostic evaluations, improving patient outcomes.
As a deep-learning-powered medical device software, Amylospot analyzes echocardiographic images with unparalleled precision, delivering clinically relevant insights that support informed decision-making. By integrating seamlessly into clinical workflows, the software helps healthcare professionals determine whether additional diagnostic testing is needed, optimizing the diagnostic pathway and ensuring that patients receive the right care at the right time.
With Amylospot, Bioquantis is revolutionizing cardiac screening by making AI-driven diagnostics accessible, efficient, and reliable—enhancing the ability of cardiologists to detect aTTR early and improve patient care worldwide.
Amylospot workflow
